Certara Earnings Call Transcripts
Fiscal Year 2026
-
Strong 2025 results were driven by disciplined cost management and targeted investments, despite volatility in services and a slowdown in software bookings. New AI-enabled products and cloud offerings are expected to drive growth, while the regulatory writing business is under strategic review.
-
Revenue and EBITDA met expectations, with 2026 growth guided at 0%-4% amid stable markets and strong biosimulation demand. New leadership is driving operational changes, AI integration, and customer-centric strategies, while maintaining disciplined investment and exploring M&A.
-
Leadership is focused on operational excellence, innovation, and customer-centric growth, with MIDD and Biosimulation as core drivers. Regulatory services remain under review, while AI integration and cloud migration are set to accelerate growth. Financial guidance anticipates low single-digit growth and stable margins.
Fiscal Year 2025
-
Q4 and full-year 2025 saw modest revenue growth, with software outpacing services. 2026 guidance is for flat to low single-digit revenue growth as operational improvements and AI integration are prioritized. Strong cash position and continued R&D investment support long-term growth.
-
Tier 3 biotech demand and biosim services growth offset Tier 1 pharma weakness, while software revenues remain stable and services bookings are more volatile. Regulatory uncertainty and FDA's NAMs directive shape the environment, with AI and cloud adoption driving product innovation, operational efficiency, and future growth.
-
Bookings slowed in Q3, especially among large clients, but biotech demand and backlog remain strong. Strategic product launches, regulatory trends favoring biosimulation, and platform integration are expected to drive growth, with software revenue acceleration targeted for 2026.
-
Q3 revenue grew 10% year-over-year to $104.6 million, with strong software and QSP performance offset by Tier 1 services softness. 2025 guidance was narrowed, with adjusted EBITDA margin raised to 32% and continued R&D investment. Tier 3 and biotech segments remain resilient.
-
Certara is accelerating growth through R&D and AI-driven software launches, including Certara IQ for QSP and cloud-based Phoenix. Despite market headwinds, strong adoption of new platforms and a robust FDA relationship support growth. Financially, margins remain stable, with ongoing M&A and a new share buyback program.
-
Certara highlighted its global leadership in biosimulation, ongoing innovation in QSP and AI-enabled platforms, and strong regulatory positioning. FDA moves to reduce animal testing and new product launches are expected to drive growth, with a focus on expanding wallet share among large biopharma clients.
-
Q2 2025 saw 12% revenue growth and 13% bookings growth, with strong performance in both software and services. EMA qualification for Simcyp and new AI-enabled product launches support a positive outlook, while guidance for 2025 is reiterated despite macroeconomic uncertainties.
-
Biosimulation is transforming drug development by reducing costs, time, and risk, with industry and regulatory adoption accelerating. The company is expanding its integrated software platform, investing in AI, and shifting its revenue mix toward high-margin software, positioning itself for significant growth.
-
Software and services performed as expected, with growth aided by acquisitions and regulatory changes favoring biosimulation. The FDA's shift away from animal testing and new product launches are driving opportunities across all customer tiers, while AI and cloud transitions are key innovation areas.
-
Q1 2025 revenue grew 10% year-over-year to $106M, with strong software and services bookings and robust interest in new non-animal testing solutions following FDA regulatory changes. Adjusted EBITDA margin reached 33%, and guidance for 2025 was reiterated.
-
Q4 saw strong bookings and margin performance, supported by acquisitions and operational improvements. While large pharma demand slowed, Simcyp and Chemaxon excelled, and biotech showed some recovery. R&D investment in cloud, AI, and product features continues, with M&A and mid-teens growth targeted as markets recover.
-
Certara highlighted its leadership in biosimulation, expanding its software and AI capabilities to improve drug development efficiency and reduce costs. Recent acquisitions and product launches, such as Chemaxon and CoAuthor, support growth, with a focus on integrating platforms and targeting underpenetrated markets.
Fiscal Year 2024
-
2024 revenue grew 9% to $385.1M, with strong Q4 bookings in both software and services. 2025 guidance calls for 8–10% revenue growth, 30–32% adjusted EBITDA margin, and continued investment in R&D and AI, with ChemAxon expected to contribute $23–$25M.
-
Industry uncertainty persists, but no direct impact is expected on biosimulation or healthcare software. Software growth is robust, driven by platform integration, new products, and strategic acquisitions like Chemaxon. Financial performance is strong, with margin improvements and a focus on further M&A and innovation.
-
Q3 2024 revenue grew 11% year-over-year, driven by strong biosimulation software and services, with Chemaxon acquisition expanding the platform. Regulatory services underperformed, prompting a strategic review and a modest guidance revision for 2024.
-
Certara is advancing its integrated biosimulation and regulatory platform, leveraging AI to drive efficiency and new product development. Recent acquisitions and cloud adoption are expanding its reach across the drug development cycle, with financials supported by strong software growth and margin discipline.
-
The business has shifted toward a stronger software focus, with AI-driven products like CoAuthor enhancing efficiency and revenue. While Tier 3 biotech customers are growing, Tier 1 pharma shows spending caution, leading to guidance toward the lower end of projections. Significant market expansion opportunities remain, with ongoing investments in AI, new modalities, and global reach.
-
Q2 2024 saw 3% revenue growth, driven by strong software performance but offset by a 3% decline in services. Cost actions and resource optimization were implemented, and full-year guidance was reiterated, with expectations tracking toward the lower end of the range. ChemAxon acquisition and new product launches are expected to support long-term growth.
-
Pharma's need for efficiency is fueling biosimulation and AI adoption, with expanding applications from preclinical to late-stage trials. Strategic acquisitions and a unified cloud portal enhance data integration and product access, supporting strong software growth and a positive revenue outlook.